HLB is taking control of changes of the future in various business fields, with
constant efforts and passion.
LSKB TO REPORT NON-CLINICAL RIVOCERANIB (APATINIB) COMBINATION WITH IMMUNOTHERAPY
SALT LAKE CITY, April 16, 2018 – LSK BioPharma (LSKB) today will present a poster at the American Association for Cancer Research (AACR) Annual Meeting in Chicago. The poster discloses nonclinical data suggesting a synergistic combination of rivoceranib (apatinib) with anti-PD-1 therapy. The combination significantly improved tumor growth suppression over each agent in monotherapy in a lung cancer mouse model study. These results are encouraging for ongoing and upcoming human clinical trials of rivoceranib in combination with the anti-PD-1 therapies nivolumab and pembrolizumab (NCT03396211, NCT03407976).